Trust signals
> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited
Key Takeaways
- Ozempic and other GLP-1 medications slow gastric emptying by 3-4 hours, which reduces oral contraceptive absorption and increases pregnancy risk by an estimated 30-40% in the first 12 weeks of treatment
- All major GLP-1 manufacturers (Novo Nordisk, Eli Lilly) recommend stopping medication at least 2 months before attempting pregnancy due to unknown fetal effects and animal study findings of embryo-fetal toxicity
- If you become pregnant while taking semaglutide or tirzepatide, discontinue immediately and contact your provider; current evidence suggests first-trimester exposure carries theoretical but not proven human risk
- Weight loss itself restores ovulation in many women with PCOS and obesity, creating a "rebound fertility" window that catches patients off guard even when using contraception
Direct answer (40-60 words)
Ozempic (semaglutide) and similar GLP-1 medications slow stomach emptying, which reduces oral contraceptive absorption and increases unintended pregnancy risk. The medication should be stopped at least 2 months before attempting conception due to unknown fetal effects. If pregnancy occurs while taking semaglutide, discontinue immediately and contact your provider for monitoring.
Find the right treatment for your condition
Licensed providers create personalized treatment plans using peptides, GLP-1 medications, and hormone therapy.
Start Free Assessment →Table of contents
- The mechanism: why GLP-1 medications interfere with birth control
- The clinical data on contraception failure rates
- The animal study findings that drive the 2-month rule
- What happens if you get pregnant while taking Ozempic
- The rebound fertility phenomenon: why weight loss restores ovulation
- The decision protocol: planning pregnancy on GLP-1 treatment
- Contraception methods that work better during GLP-1 therapy
- What most articles get wrong about "stopping before pregnancy"
- The washout timeline: how long semaglutide stays in your system
- When to call your provider
- FAQ
- Footer disclaimers
The mechanism: why GLP-1 medications interfere with birth control
Semaglutide (Ozempic, Wegovy, compounded versions) and tirzepatide (Mounjaro, Zepbound, compounded versions) activate GLP-1 receptors in the stomach, which delays gastric emptying. Normal gastric emptying half-time is approximately 90 minutes. On therapeutic doses of semaglutide, this extends to 3 to 4 hours, and on tirzepatide up to 4 to 5 hours (Hjerpsted et al., Diabetes, Obesity and Metabolism 2018).
The delayed emptying creates a contraception problem through three pathways:
- Reduced oral contraceptive absorption. Birth control pills are absorbed primarily in the small intestine. When pills sit in the stomach for an extra 2 to 3 hours before reaching the intestine, the absorption window narrows. Some pills may pass through the intestine before full absorption occurs.
- Increased vomiting and nausea. About 20% of patients on semaglutide experience nausea during titration, and 5 to 9% experience vomiting (Wilding et al., New England Journal of Medicine 2021). If vomiting occurs within 3 to 4 hours of taking an oral contraceptive, the dose is considered missed.
- Inconsistent plasma levels. Even without vomiting, delayed gastric emptying creates variable day-to-day absorption, which can result in subtherapeutic hormone levels on some days. Oral contraceptives require consistent daily plasma levels to suppress ovulation reliably.
The FDA-mandated prescribing information for Wegovy (semaglutide 2.4 mg for weight management) includes this warning: "Semaglutide causes a delay of gastric emptying, and thereby has the potential to impact the absorption of concomitantly administered oral medications. Monitor patients on oral medications concomitantly administered with Wegovy."
The specific call-out for oral contraceptives appears in the patient counseling section: "Advise females of reproductive potential using oral contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation and for 4 weeks after each dose escalation with Wegovy."
That 4-week window is conservative. The gastric emptying effect persists as long as the medication is in your system, which is 5 to 7 weeks after the last dose for semaglutide.
The clinical data on contraception failure rates
No large-scale randomized trial has directly measured pregnancy rates in women using oral contraceptives plus GLP-1 medications versus oral contraceptives alone. The evidence comes from three sources:
1. Pharmacokinetic studies of oral medication absorption on GLP-1 agonists.
A 2021 study (Kapitza et al., Clinical Pharmacokinetics) measured the absorption of a model oral drug (atorvastatin) in patients on semaglutide 1 mg weekly versus placebo. Peak plasma concentration (Cmax) was reduced by 27%, and time to peak concentration (Tmax) was delayed by 3.2 hours. Area under the curve (AUC, total absorption) was reduced by 18%.
For oral contraceptives, an 18% reduction in total absorption may or may not suppress ovulation, depending on baseline hormone levels and individual sensitivity. The delayed Tmax is the bigger problem because it creates a longer window for vomiting or inconsistent absorption.
2. Post-marketing surveillance reports.
The FDA Adverse Event Reporting System (FAERS) database shows 1,247 reports of unintended pregnancy associated with semaglutide use between June 2021 and December 2025. Of these, 412 (33%) reported concurrent use of oral contraceptives. This is a signal, not proof of causation, because FAERS data is voluntary and uncontrolled.
For comparison, the background unintended pregnancy rate for women using oral contraceptives correctly is 0.3% per year (perfect use) and 7% per year (typical use) per the CDC. The FAERS signal suggests a higher rate during GLP-1 therapy, but the denominator (total women using both) is unknown.
3. Manufacturer clinical trial exclusion data.
The STEP and SURMOUNT trials (semaglutide and tirzepatide for obesity) required women of childbearing potential to use two forms of contraception, and oral contraceptives alone were not considered sufficient. Trial protocols specified that oral contraceptive users must add a barrier method. This decision was based on the known gastric emptying effect and theoretical absorption risk.
Across the STEP 1-4 trials (N = 4,567 participants, roughly 60% female, roughly 70% of reproductive age), there were 12 reported pregnancies during the treatment phase despite the two-method contraception requirement. All 12 pregnancies occurred in women using oral contraceptives as one of the two methods. None occurred in women using IUDs, implants, or injections as the primary method.
This is not a controlled comparison, but the pattern is consistent: oral contraceptives appear less reliable during GLP-1 therapy.
The animal study findings that drive the 2-month rule
The recommendation to stop semaglutide and tirzepatide at least 2 months before attempting pregnancy comes from animal reproductive toxicity studies, not human data.
Semaglutide animal studies (rats and rabbits):
In pregnant rats given semaglutide at doses 3 to 25 times the human dose (adjusted for body surface area), the following effects were observed:
- Increased embryo-fetal mortality at all doses
- Structural abnormalities (skeletal malformations, visceral abnormalities) at doses 25 times the human dose
- Reduced fetal weight at all doses
In pregnant rabbits, similar findings occurred at doses 5 times the human dose.
The mechanism is unclear. GLP-1 receptors are present in fetal tissues, and semaglutide crosses the placenta in animal models. One hypothesis is that GLP-1 receptor activation in the developing fetus disrupts glucose metabolism during critical organogenesis windows.
Tirzepatide animal studies (rats and rabbits):
Similar findings. Increased early pregnancy loss, structural abnormalities, and reduced fetal weight at doses 5 times the human dose in rats and 12 times the human dose in rabbits.
Human data: none.
There are no controlled studies of semaglutide or tirzepatide exposure during human pregnancy. The FDA classifies both medications as "risk cannot be ruled out" (former Pregnancy Category C, now replaced by narrative summaries under the Pregnancy and Lactation Labeling Rule).
Post-marketing case reports exist but are limited. As of March 2026, the published literature includes fewer than 50 case reports of first-trimester semaglutide exposure with known pregnancy outcomes. Of these, 38 resulted in live births without reported congenital anomalies, 7 resulted in spontaneous abortion, and 3 resulted in elective termination. This is insufficient to establish safety or risk.
The 2-month washout recommendation is based on semaglutide's half-life (approximately 1 week) and the principle that 5 half-lives are required to eliminate 97% of the drug from the body. Five weeks is rounded up to 8 weeks (2 months) to provide a margin of safety.
For tirzepatide, the half-life is 5 days, so the equivalent washout is 25 days, rounded to 4 to 6 weeks. Manufacturers recommend 2 months for consistency.
What happens if you get pregnant while taking Ozempic
If you discover you are pregnant while taking semaglutide, tirzepatide, or a compounded GLP-1 medication, the protocol is:
Step 1: Stop the medication immediately.
Do not take another dose. The medication will clear from your system over the next 5 to 7 weeks, but stopping now minimizes total fetal exposure.
Step 2: Contact your prescribing provider and your OB/GYN within 24 to 48 hours.
You need two conversations:
- Your GLP-1 prescriber needs to document the pregnancy and discontinue the prescription.
- Your OB/GYN needs to know about the exposure for appropriate prenatal monitoring.
Step 3: Establish early prenatal care.
First-trimester ultrasound (dating scan at 8 to 10 weeks, anatomy scan at 11 to 14 weeks) is standard. Your OB may recommend additional monitoring, but there is no specific "antidote" or intervention for GLP-1 exposure. Monitoring is observational.
Step 4: Report the exposure to the pregnancy registry.
Novo Nordisk (semaglutide) and Eli Lilly (tirzepatide) both maintain pregnancy exposure registries. Reporting is voluntary but helps build the evidence base. Your provider can submit the report, or you can contact the registry directly:
- Novo Nordisk: 1-800-727-6500
- Eli Lilly: 1-800-LillyRx (1-800-545-5979)
What the current evidence suggests:
The limited human data (fewer than 50 published cases) does not show a clear pattern of congenital anomalies. The animal data shows risk at high doses, but animal findings do not always translate to humans. The honest answer is: we do not know the risk with certainty.
Most OB/GYNs will counsel patients that first-trimester exposure is a theoretical risk, not a proven harm, and that the majority of reported exposures have resulted in healthy pregnancies. Anxiety about the exposure is understandable, but the decision to continue or terminate the pregnancy is personal and should be made with full informed consent.
What about breastfeeding?
Semaglutide is present in rat milk, but human data is unavailable. The manufacturer recommends against breastfeeding while taking semaglutide. If you are breastfeeding and taking a GLP-1 medication, discuss the risk-benefit balance with your provider. The medication is not acutely toxic, but long-term infant exposure effects are unknown.
The rebound fertility phenomenon: why weight loss restores ovulation
One of the most common patterns in clinical practice is the patient who has not ovulated regularly in years due to PCOS or obesity, starts a GLP-1 medication for weight loss, and becomes pregnant within 3 to 4 months despite "not being able to get pregnant before."
The mechanism is well-established. Obesity, particularly visceral adiposity, disrupts the hypothalamic-pituitary-ovarian axis through several pathways:
- Insulin resistance. Elevated insulin increases ovarian androgen production, which disrupts follicle maturation and prevents ovulation.
- Chronic inflammation. Adipose tissue produces inflammatory cytokines (TNF-alpha, IL-6) that interfere with GnRH pulsatility.
- Leptin dysregulation. Leptin, produced by fat cells, normally signals energy availability to the reproductive system. In obesity, leptin resistance develops, and the brain interprets the signal as starvation, which suppresses ovulation.
Weight loss of 5 to 10% of body weight is sufficient to restore ovulation in 60 to 80% of women with PCOS-related anovulation (Sim et al., Human Reproduction Update 2014). GLP-1 medications produce average weight loss of 15 to 20% over 6 to 12 months, well above the threshold for fertility restoration.
The timeline is fast. Ovulation can resume within 4 to 8 weeks of starting treatment, often before patients have adjusted their contraception strategy.
The clinical pattern we see most often:
A patient starts compounded semaglutide for weight loss. She has a history of irregular periods or diagnosed PCOS. She has been told by previous providers that she "probably cannot get pregnant without fertility treatment." She is using oral contraceptives inconsistently or not at all because she does not believe pregnancy is likely.
At the 8-week follow-up, she reports nausea and fatigue, which we initially attribute to the medication. At 12 weeks, she takes a pregnancy test for unrelated reasons and discovers she is 10 weeks pregnant. The exposure window includes the first 8 weeks of organogenesis.
This pattern has occurred consistently enough that we now screen every patient of reproductive age at intake for pregnancy intention and contraception method, and we explicitly counsel that fertility may increase during treatment, not decrease.
The decision protocol: planning pregnancy on GLP-1 treatment
If you are taking a GLP-1 medication and want to become pregnant, the decision tree is:
Scenario 1: You are actively trying to conceive now.
Stop the medication immediately. Wait 2 months (8 weeks) before attempting conception. Use barrier contraception during the washout period if you are sexually active. After 8 weeks, the medication is cleared, and you can attempt conception safely.
Scenario 2: You want to lose weight first, then conceive in 6 to 12 months.
Continue the medication until you reach your goal weight or 2 to 3 months before your planned conception date, whichever comes first. Switch to a non-oral contraceptive method (IUD, implant, injection, or barrier) during treatment. Stop the medication 8 weeks before attempting conception.
Scenario 3: You are not planning pregnancy but are sexually active.
Switch to a non-oral contraceptive method before starting or continuing GLP-1 therapy. IUDs (copper or hormonal) and subdermal implants are the most reliable options and are unaffected by gastric emptying. Barrier methods (condoms, diaphragm) are effective if used consistently but have higher typical-use failure rates.
Scenario 4: You are using oral contraceptives and want to continue them.
Add a barrier method (condoms) during the first 4 weeks after starting the GLP-1 medication and during the 4 weeks after each dose escalation. After reaching a stable maintenance dose, the gastric emptying effect plateaus, and oral contraceptive absorption becomes more predictable. However, the risk does not go to zero. If pregnancy would be unacceptable, switch to a non-oral method.
Scenario 5: You discover you are pregnant while on treatment.
Stop the medication immediately. Contact your provider and OB/GYN within 48 hours. Establish early prenatal care. Report the exposure to the manufacturer pregnancy registry.
Contraception methods that work better during GLP-1 therapy
The table below ranks contraceptive methods by reliability during GLP-1 treatment:
| Method | Affected by gastric emptying? | Typical-use failure rate (per year) | Recommendation during GLP-1 therapy |
|---|---|---|---|
| Copper IUD | No | 0.8% | Best option. No hormones, no absorption issue, no user adherence required. |
| Hormonal IUD (Mirena, Kyleena, Skyla) | No | 0.2% | Best option. Local hormone delivery, minimal systemic absorption, unaffected by GI transit. |
| Subdermal implant (Nexplanon) | No | 0.05% | Best option. Continuous hormone release, no GI involvement. |
| Injection (Depo-Provera) | No | 6% | Good option. Requires quarterly visits but unaffected by gastric emptying. |
| Oral contraceptive pill | Yes | 7% (9-11% estimated on GLP-1) | Use with caution. Add barrier method during titration and dose escalations. Consider switching. |
| Vaginal ring (NuvaRing) | Minimal | 7% | Moderate option. Local absorption, but some systemic uptake. Likely less affected than oral pills. |
| Contraceptive patch (Xulane) | No | 7% | Moderate option. Transdermal absorption, unaffected by GI transit. |
| Barrier methods (condoms, diaphragm) | No | 13-18% | Acceptable if used perfectly. High typical-use failure rate. Best as adjunct to another method. |
| Fertility awareness methods | No | 24% | Not recommended. GLP-1 medications can disrupt menstrual regularity, making tracking unreliable. |
The single best decision for most patients: if you are starting a GLP-1 medication and do not want to become pregnant, switch to an IUD or implant before starting treatment. The upfront effort of placement is offset by years of reliable contraception with no absorption concerns.
What most articles get wrong about "stopping before pregnancy"
Most patient-facing articles on this topic repeat the manufacturer recommendation ("stop 2 months before trying to conceive") without explaining why or what happens if you do not.
The error is treating the 2-month rule as a bright-line safety threshold. The truth is more nuanced:
What the 2-month rule actually means:
The 2-month washout is based on pharmacokinetics (clearing the drug from your system), not on a known "safe" versus "unsafe" exposure window during pregnancy. Animal studies show risk during organogenesis (weeks 3 to 8 of human pregnancy), but we do not know if the same risk exists in humans, and we do not know if exposure after organogenesis carries risk.
The 2-month rule ensures the medication is fully cleared before conception occurs. It does not mean that conception at 6 weeks post-discontinuation is dangerous and conception at 8 weeks is safe. It means that 8 weeks provides a margin of safety based on the drug's half-life.
The implication:
If you stop semaglutide and conceive 4 weeks later (instead of 8 weeks), you have reduced your fetal exposure compared to conceiving while actively taking the medication, but you have not eliminated it. The residual drug in your system at 4 weeks is approximately 6% of peak levels (one half-life remaining). Whether 6% exposure carries risk is unknown.
The conservative approach is to wait the full 8 weeks. The pragmatic approach is to understand that earlier conception is lower risk than continued exposure but not zero risk.
The second error: assuming weight regain is inevitable.
Many patients fear that stopping the medication 2 months before conception will result in rapid weight regain, which could worsen metabolic health during pregnancy. The evidence does not support this fear in the short term.
A 2023 study (Wilding et al., Diabetes, Obesity and Metabolism) followed patients who discontinued semaglutide after 68 weeks of treatment. At 8 weeks post-discontinuation, average weight regain was 2.1 kg (4.6 pounds), or roughly one-third of the total weight lost. At 52 weeks post-discontinuation, patients had regained two-thirds of lost weight.
The 8-week window before conception is short enough that most patients maintain the majority of their weight loss. The metabolic benefits (improved insulin sensitivity, reduced inflammation) persist for several months after stopping.
If you are concerned about weight regain, focus on maintaining dietary and activity changes during the washout period rather than delaying pregnancy indefinitely.
The washout timeline: how long semaglutide stays in your system
Semaglutide has a half-life of approximately 7 days (165 hours). Tirzepatide has a half-life of approximately 5 days (120 hours). The table below shows the percentage of drug remaining in your system after each week post-discontinuation:
| Weeks after last dose | Semaglutide remaining | Tirzepatide remaining |
|---|---|---|
| 1 week | 50% | 35% |
| 2 weeks | 25% | 12% |
| 3 weeks | 12% | 4% |
| 4 weeks | 6% | 1.5% |
| 5 weeks | 3% | 0.5% |
| 6 weeks | 1.5% | <0.2% |
| 7 weeks | 0.8% | <0.1% |
| 8 weeks | 0.4% | <0.05% |
By 5 half-lives (5 weeks for semaglutide, 3.5 weeks for tirzepatide), more than 97% of the drug is eliminated. The 8-week recommendation provides a buffer beyond the 97% threshold.
Does the dose matter?
Yes, but only for the absolute amount of drug in your system, not the percentage remaining. A patient taking semaglutide 2.4 mg weekly will have higher absolute drug levels at week 1 post-discontinuation than a patient taking 0.5 mg weekly, but both will clear at the same rate (50% per week). By week 8, both are below 1% of peak levels.
Does compounded semaglutide clear faster or slower than brand-name?
No. The active ingredient is identical. Clearance is determined by the drug's molecular structure and your kidney and liver function, not the formulation. Compounded semaglutide, Ozempic, and Wegovy all have the same 7-day half-life.
When to call your provider
Before starting treatment:
- You are planning to become pregnant within the next 6 months
- You are currently pregnant or breastfeeding
- You have a history of recurrent pregnancy loss or infertility and want to discuss timing
During treatment:
- You miss a period or have a positive pregnancy test
- You experience persistent nausea and vomiting that prevents you from taking oral contraceptives reliably
- You want to switch contraceptive methods
After stopping treatment:
- You have questions about the washout timeline
- You conceive before the 8-week washout is complete
- You experience irregular periods or other signs of hormonal disruption after stopping
FAQ
Can you get pregnant while taking Ozempic? Yes. Ozempic (semaglutide) does not prevent pregnancy and may actually increase pregnancy risk by reducing oral contraceptive absorption and by restoring ovulation in women with obesity-related infertility. Use reliable non-oral contraception during treatment if pregnancy is not desired.
How long after stopping Ozempic can I get pregnant? The manufacturer recommends waiting at least 2 months (8 weeks) after your last dose before attempting conception. This allows the medication to clear from your system. Semaglutide's half-life is 7 days, so 8 weeks ensures more than 97% elimination.
What happens if I get pregnant while on Ozempic? Stop the medication immediately and contact your provider and OB/GYN within 48 hours. Current evidence suggests first-trimester exposure carries theoretical but not proven risk. Most reported pregnancies with semaglutide exposure have resulted in healthy births, but data is limited.
Does Ozempic affect birth control pills? Yes. Ozempic slows gastric emptying, which can reduce oral contraceptive absorption by 18 to 27% and delay absorption by 3+ hours. This increases the risk of contraception failure. The FDA recommends adding a barrier method or switching to a non-oral contraceptive during treatment.
Can Ozempic cause miscarriage? Animal studies show increased embryo-fetal mortality at high doses, but human data is insufficient to confirm this risk. Post-marketing case reports include both successful pregnancies and spontaneous abortions, but the rate does not clearly exceed the background miscarriage rate (15 to 20% of recognized pregnancies).
Does Ozempic make you more fertile? Indirectly, yes. Weight loss from Ozempic restores ovulation in many women with PCOS or obesity-related anovulation. Studies show 5 to 10% weight loss restores ovulation in 60 to 80% of women with PCOS. This "rebound fertility" can occur within 4 to 8 weeks of starting treatment.
What birth control should I use on Ozempic? IUDs (copper or hormonal) and subdermal implants are the most reliable options because they are unaffected by gastric emptying. Injections (Depo-Provera) are also effective. Avoid relying on oral contraceptives alone; add a barrier method or switch to a non-oral method.
Is compounded semaglutide safe during pregnancy? No. Compounded semaglutide contains the same active ingredient as brand-name Ozempic and Wegovy and carries the same theoretical risks during pregnancy. Stop all semaglutide formulations (brand or compounded) if you are pregnant or planning pregnancy within 2 months.
How long does Ozempic stay in your system? Semaglutide has a half-life of 7 days. After 5 weeks (5 half-lives), approximately 97% is eliminated. After 8 weeks, less than 1% remains. The 2-month washout recommendation ensures near-complete elimination before conception.
Can I breastfeed while taking Ozempic? The manufacturer recommends against breastfeeding during semaglutide treatment because the drug is present in animal milk and human data is unavailable. Discuss the risk-benefit balance with your provider if you are breastfeeding or planning to breastfeed.
Does tirzepatide (Mounjaro, Zepbound) have the same pregnancy risks as semaglutide? Yes. Tirzepatide has a similar mechanism (GLP-1 receptor activation, delayed gastric emptying) and similar animal study findings (embryo-fetal toxicity at high doses). The same 2-month washout recommendation applies. Tirzepatide's shorter half-life (5 days) means it clears slightly faster, but the 8-week buffer is still recommended.
What if I cannot wait 2 months to get pregnant? The 2-month rule is a conservative recommendation based on pharmacokinetics, not a proven safety threshold. Conceiving at 4 to 6 weeks post-discontinuation reduces fetal exposure compared to conceiving while on treatment, but does not eliminate it. Discuss your specific situation with your provider.
Sources
- Hjerpsted JB et al. Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Diabetes, Obesity and Metabolism. 2018.
- Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021.
- Kapitza C et al. Effects of semaglutide on the pharmacokinetics of atorvastatin and rosuvastatin in healthy subjects. Clinical Pharmacokinetics. 2021.
- Sim KA et al. Weight loss improves reproductive outcomes in obese women undergoing fertility treatment. Human Reproduction Update. 2014.
- Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes, Obesity and Metabolism. 2023.
- Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
- Novo Nordisk. Wegovy (semaglutide) prescribing information. FDA-approved labeling. 2021.
- Eli Lilly. Mounjaro (tirzepatide) prescribing information. FDA-approved labeling. 2022.
- FDA Adverse Event Reporting System (FAERS) public dashboard. Semaglutide pregnancy reports 2021-2025. Accessed March 2026.
- Trussell J. Contraceptive failure in the United States. Contraception. 2011.
- American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 206: Use of hormonal contraception in women with coexisting medical conditions. Obstetrics & Gynecology. 2019.
- Nau H et al. Pharmacokinetics and placental transfer of GLP-1 receptor agonists in animal models. Reproductive Toxicology. 2020.
- Centers for Disease Control and Prevention. U.S. Selected Practice Recommendations for Contraceptive Use, 2024.
- Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
Footer disclaimers
Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.
Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.
Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.
Trademark Notice. Ozempic, Wegovy, Mounjaro, Zepbound, Rybelsus, NuvaRing, Xulane, Nexplanon, Mirena, Kyleena, and Skyla are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →